

PATENT SPECIFICATION

(11) 1412856

1412856

- (21) Application No. 20348/73 (22) Filed 30 April 1973
 (31) Convention Application No. 252078 (32) Filed 10 May 1972
 (31) Convention Application No. 349876 (32) Filed 12 April 1973 in
 (33) United States of America (US)
 (44) Complete Specification published 5 Nov. 1975
 (51) INT. CL.³ C07D 501/16//C07F 7/10
 (52) Index at acceptance




C2C 1314 1341 1344 1414 1432 1464 1470 1510 213 214
 215 220 226 22Y 247 250 251 252 253 254 255
 256 25Y 28X 292 29Y 305 30Y 313 315 31Y 321
 32Y 332 339 33Y 342 34Y 351 352 364 366 367
 368 36Y 373 37Y 384 387 43X 613 621 628 62X
 645 650 659 65X 661 662 663 66X 670 673 678
 681 699 761 762 763 790 KE LX MM RP SU TP
 C3S 2 3A 3D 5 6 7B 7C 7D 9

(54) PROCESS FOR PREPARING DESACETOXYCEPHALOSPORINS AND NOVEL INTERMEDIATES


(71) We, ELI LILLY AND COMPANY a Corporation organised and existing under the laws of the State of Indiana, United States of America, of 307 East McCarty Street, Indianapolis, Indiana, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

The present invention provides a process for converting a penicillin sulfoxide to a desacetoxycephalosporin which comprises heating the penicillin sulfoxide in an inert, substantially anhydrous solvent to a temperature of from about 75°C to about 150°C in the presence of a silylating agent containing at least one readily cleavable moiety having the formula $-\text{Si}(\text{R}_1)_3$ in which each R_1 independently is C_1-C_4 alkyl or phenyl, and either isolating a stable intermediate silyl ester of an azetidine - 2 - sulfenate and subsequently converting ester to the corresponding desacetoxycephalosporin by treatment thereof with an acidic compound in an inert substantially anhydrous solvent, or without isolation, converting the intermediate silyl ester to the corresponding desacetoxycephalosporin by treating the reaction mixture with an acidic compound.


Also the present invention provides silyl esters of azetidine - 2 - sulfenates of the formula II



in which each R_1 independently is C_1-C_4 alkyl or phenyl; R_2 is C_1-C_8 alkyl, 2,2,2-trihaloethyl, 2-iodoethyl, benzyl, nitrobenzyl, tetrahydropyranyl, 9-fluorenyl, succinimido-methyl, phthalimidomethyl, methoxybenzyl, dimethoxybenzyl, cyanomethyl, nitrophenyl, dinitrophenyl, 2,4,6-trinitrophenyl, bis - (*p*-methoxyphenyl)methyl, triphenylmethyl, benzhydryl, benzyloxymethyl, C_2-C_6 alkanoyloxymethyl, C_2-C_4 alkanoyl, phenacyl or a radical of the formula




in which each R_1 is as herein defined, R_2 is hydrogen and R_4 is C_1-C_8 alkanoyl, azidoacetyl; cyanoacetyl; haloacetyl;




in which Ar is phenyl, thienyl, furyl, pyrrolyl, or phenyl substituted with from one to three substituents selected from the group consisting of fluorine, chlorine, bromine, iodine, trifluoromethyl, C₁-C₃ acyloxy, —OSi(R₁)₃, C₁-C₃ alkyl, C₁-C₃ alkoxy, cyano, and nitro;



in which Ar' is phenyl, pyridyl, or substituted phenyl as defined above, and Y is oxygen or sulfur;




in which Ar is as defined above, and B is C₁-C₃ acyloxy,



- 15 esterified carboxyl, —CN, —N₃, or —NHR in which R is benzyloxycarbonyl, C₁-C₄ alkoxy carbonyl, cycloalkoxy carbonyl, triphenylmethyl,



- 20 2,2,2-trichloroethoxycarbonyl, or —Si(R₁)₃ in which R₁ is as herein defined; (3-sydnone) C₂-C₃ alkanoyl;



- in which R' is hydrogen or methoxy; 2 - (1H - tetrazol - 1 - yl)acetyl; or R₃ and R₄ taken together with the nitrogen atom to which they are bonded are phthalimido, a cyclic imide moiety of a C₃-C₁₂ dicarboxylic acid, 2,2 - dimethyl - 5 - oxo - 4 - phenylimidazolidin - 1 - yl, or 2,2 - dimethyl - 3 - nitroso - 5 - oxo - 4 - phenylimidazolidin - 1 - yl.

- The semisynthetic production of a 7-acylamidodesacetoxycephalosporin antibiotic from a penicillin starting material has been of exceptional importance since the advent of the invention of Morin and Jackson (U.S. Patent No. 3,275,626) who describe and claim a process for converting a penicillin sulfoxide ester to a desacetoxycephalosporanic acid ester. Subsequently, improvements were made upon this Morin-Jackson process. Robin D. G. Cooper found that the use of certain tertiary carboxamide solvents (British Patent No.


1,204,972) or certain tertiary sulfonamide solvents (British Patent No. 1,204,394) directed the heat rearrangement of the penicillin sulfoxide esters more specifically toward production of the corresponding desacetoxycephalosporin esters and permitted the use of lower temperatures. Hatfield (U.S. Patent No. 3,591,585) improved upon the Cooper contributions by finding that the conversion of a penicillin sulfoxide ester to a desacetoxycephalosporin ester by heating under acid conditions in the presence of a tertiary carboxamide solvent can be further improved by carrying out the reaction in the presence of both a sulfonic acid and a means for removing or inactivating water present in the reaction mixture.

The mechanism which is postulated in U.S. Patent No. 3,275,626 for the conversion of the penicillin sulfoxide ester to a desacetoxycephalosporanic acid ester is by formation of a sulfenic acid involving scission of the S—C₂ bond. This mechanism has now been conclusively established, and it furthermore has been shown (R. D. G. Cooper, *J.A.C.S.*, 92, (1970) pp. 5010—5011) that, under the conditions of reaction, a thermal equilibrium between the sulfoxide starting material and the sulfenic acid intermediate is established. One approach which would be advantageous in accomplishing the desired conversion of a penicillin sulfoxide or ester derivative thereof to its corresponding desacetoxycephalosporanic acid or ester derivative would be to trap the fleeting and unstable sulfenic acid intermediate in the form of a stable and isolatable intermediate. This intermediate could then be isolated and subsequently converted to the corresponding desacetoxycephalosporin or could be formed under conditions which, without isolation, would permit a virtual immediate conversion to the corresponding desacetoxycephalosporin.

The novel silyl esters exhibit a sufficient degree of stability to render them isolatable and amenable to characterization. In the above formula the silicon atom is bonded to three groups characterized by R₁. Each R₁ independently is defined as C₁-C₄ alkyl or phenyl. Typical of the silyl radicals which can be present in the novel ester intermediates of this invention are trimethylsilyl, triphenylsilyl, methyl diethylsilyl, propyldimethylsilyl, and the like. Generically, the esters can be named as silyl esters of azetidine - 2 - sulfenates.


The group R₂ in the above formula is a carboxy protecting group. Such groups and their use are well known in the penicillin and cephalosporin arts and need no specific exemplification since the man skilled in the art is well aware of the large number of such groups which are available. Preferred carboxy protecting groups include, for example, C₁-C₆ alkyl, 2,2,2-trihaloethyl, 2-iodoethyl,

- benzyl, nitrobenzyl, tetrahydropyranyl, 9-fluorenyl, succinimidomethyl, phthalimidomethyl, methoxybenzyl, dimethoxybenzyl, cyanomethyl, nitrophenyl, dinitrophenyl, 2,4,6-trinitrophenyl, bis(*p*-methoxyphenyl)methyl, triphenylmethyl, benzhydryl, benzyloxymethyl, C₂—C₆ alkanoyloxymethyl, C₂—C₄ alkanoyl, phenacyl, or a radical of the formula



- 10 in which each R₁ is as defined hereinabove, and the like.


- In the above formula, R₃ and R₄ denote an amino protecting group. Such groups and their use are now well recognized in the penicillin and cephalosporin art and need no specific exemplification. Preferred amino protecting groups include, for example, the combination of R₃ being hydrogen and R₄ being C₁—C₈ alkanoyl; azidoacetyl; cyanoacetyl; haloacetyl;



- in which Ar is phenyl, thienyl, furyl, pyrrolyl, or phenyl substituted with from one to three substituents selected from the group consisting of fluorine, chlorine, bromine, iodine, trifluoromethyl, C₁—C₃ acyloxy, —OSi(R₁)₃, C₁—C₃ alkyl, C₁—C₃ alkoxy, cyano, and nitro;



- 30 in which Ar' is phenyl, pyridyl, or substituted phenyl, as defined above, and Y is oxygen or sulfur;




- in which Ar is as defined above, and B is C₁—C₃ acyloxy,



- 35 esterified carboxyl, —CN, —N₃, or —NHR in which R is benzyloxycarbonyl, C₁—C₄ alkoxycarbonyl, cycloalkoxycarbonyl, triphenylmethyl,

- 40 CH₃C=CH—CO₂CH₃,

2,2,2-trichloroethoxycarbonyl, or —Si(R₁)₃ in which R₁ is as herein defined; (3-syndnone) C₂—C₃ alkanoyl;



in which R' is hydrogen or methoxy; 2 - (1H - tetrazol - 1 - yl)acetyl; and the like. Additional preferred amino protecting groups are those defined by R₃ and R₄ taken together with the nitrogen atom to which they are bonded, and include, for example, phthalimido, a cyclic imide moiety of a C₈—C₁₂ dicarboxylic acid, 2,2 - dimethyl - 5 - oxo - 4 - phenylimidazolidin - 1 - yl, 2,2 - dimethyl - 3 - nitroso - 5 - oxo - 4 - phenylimidazolidin - 1 - yl, or the like.

The novel silyl esters described above are intermediates in the conversion of penicillin sulfoxides to desacetoxyccephalosporins. As has been developed in detail in Morin et al., *Journal of the American Chemical Society*, 91, (1969) pp. 1401—1407, ring expansion of penicillins to cephalosporins involves an oxidative cleavage of the C₂-sulfur bond producing a labile sulfenic acid intermediate having a double bond at the C₂-carbon. This intermediate is subsequently ring closed to achieve a 3-cephem cephalosporin. Due to the equilibrium characteristics of the reaction as it bears on the sulfenic acid intermediate, it is possible for the sulfenic acid to ring close to the 3-cephem cephalosporin or to revert to the penicillin structure. Therefore, it is highly desirable to trap the sulfenic acid intermediate in the form of a stable derivative which can then be further reacted to achieve the desired cephalosporin product. It is precisely such a process which is defined as another aspect of this invention.


The process of this invention is distinguishable from prior uses of silicon-containing compounds in conjunction with penicillin sulfoxides. Gutowski, *Tetrahedron Letters*, 21, (1970) pp. 1779—1782, describes the epimerization of penicillin sulfoxide esters when exposed to a silylating agent at room temperature for several days. Belgian Patent No. 763,104 teaches a process for reacting a penicillin sulfoxide by heating the sulfoxide to a temperature below 160°C. in an anhydrous medium and in the presence of a compound containing silicon and halogen and at least one nitrogenous base present in a quantity of at least 5 moles per mole of the sulfoxide.

In the process of this invention any silylating agent can be employed which will achieve the silylation of the sulfenic acid intermediate formed by thermal cleavage of the penicillin sulfoxide. Any such silylating agent will contain at least one moiety having the formula —Si(R₁)₃ in which R₁ is as herein defined,

10


and, furthermore, such moiety will be so situated in the silylating agent molecule as to be readily cleavable therefrom under the conditions of reaction and thereby available for forming the azetidine - 2 - sulfenyl ester. Mixtures of silylating agents can likewise be employed. Preferably, any mixture of silylating agents will be such that each silylating agent will give rise to the same silyl protecting group. Preferred silylating agents include those having the following formulae:

(a)



in which each R_1 independently is C_1 - C_4 alkyl or phenyl, R''' is hydrogen, C_1 - C_4 alkyl, or phenyl, and X is


15



in which J is hydrogen or $-\text{Si}(\text{R}_1)_3$ in which each R_1 is as defined hereinabove, or X is $-\text{CW}_3$ in which each W independently is hydrogen, trifluoromethyl, or C_1 - C_3 alkyl;

20

(b)



in which R_1 and W are as herein defined; and

25

(c)




in which R_1 is as herein defined and Z is halogen, C_2 - C_3 alkenyloxy, C_1 - C_3 alkyl $-\text{SO}_3-$,

30



in which each R_1 is as defined hereinabove, or



35

in which R_5 is hydrogen or C_1 - C_3 alkyl, and R_6 is C_1 - C_4 alkyl or $-\text{Si}(\text{R}_1)_3$ in which each R_1 is as defined hereinabove, or R_5 and R_6 taken together with the

nitrogen atom to which they are bonded form a heterocyclic ring having 5 or 6 atoms, up to 3 of which, in addition to the already-defined nitrogen atom, independently are nitrogen, sulfur, or oxygen.

40

Of the above preferred silylating agents, it is more preferred that R_1 defined therein is phenyl, or, taken from the C_1 to C_4 alkyl definition, methyl. Most preferably, R_1 is methyl.

45

Typical examples of the silylating agents which can be employed in the process of this invention include: N_2O - bis(trimethylsilyl)acetamide, N_2O - bis(triethylsilyl)acetamide, N_2O - bis(triphenylsilyl)acetamide, N_2O - bis(trimethylsilyl)trifluoroacetamide, N_2O - bis(tripropylsilyl)trifluoroacetamide, N_2O - bis(triphenylsilyl)trifluoroacetamide, N - trimethylsilylacetamide, N - tributylsilylacetamide, N - triphenylsilylacetamide, N - methyl - N - trimethylsilylacetamide, N - ethyl - N - triethylsilylacetamide, N - methyl - N - triphenylsilylacetamide, N - trimethylsilyl - N,N' - diphenylurea, N - triethylsilyl - N,N' - diphenylurea, N - triphenylsilyl - N,N' - diphenylurea, propenoxytrimethylsilane, ethenoxytriethylsilane, propenoxytriphenylsilane, trimethylsilylmethane sulfonate, tripropylsilyl ethane sulfonate, triphenylsilyl propane sulfonate, trimethylchlorosilane, triethylchlorosilane, triphenylchlorosilane, hexamethyldisilazane, hexaethyldisilazane, hexaphenyldisilazane, N - trimethylsilyl - t - butylamine, N - tripropylsilyl - t - butylamine, N - triphenylsilyl - t - butylamine, N - trimethylsilyldiethylamine, N - triethylsilyldimethylamine, N - triphenylsilylmethylethylamine, N - trimethylsilylimidazole, N - triethylsilylimidazole, N - triphenylsilylimidazole, hexamethyldisiloxane, hexapropyldisiloxane, hexaphenyldisiloxane, hexamethyldisilthiane, hexaethyldisilthiane and hexaphenyldisilthiane.

50

55

60

65

70

75

80

85

90

95

The conversion of the penicillin sulfoxide in accordance with the process of this invention is accomplished by heating the sulfoxide with the chosen silylating agent to a temperature of from about 75°C . to about 150°C . The heating of the sulfoxide is carried out in the presence of an appropriate inert, substantially anhydrous solvent. Any solvent can be employed which is inert to the penicillin sulfoxide and to the silylating agent and which has a sufficiently elevated boiling point to achieve the necessary reaction temperature. Suitable solvents include benzene, toluene, acetonitrile, dioxane, dimethylformamide, and dimethylacetamide. Mixtures of appropriate solvents can also be employed.

The reaction mixture containing the penicillin sulfoxide is heated in the presence of a silylating agent at a temperature within the above range for a period necessary to effect conversion. This period can be very short or somewhat longer depending upon the react-

100

ants which are employed. Generally, the mixture will be heated for a period of from about 0.5 hours to about 24 hours. It is believed that the application of heat to the sulfoxide accomplishes a scission of the sulfur-C₂ bond. The scission of the sulfur-C₂ bond gives rise to a sulfenic acid type intermediate which is susceptible to attack by the silylating agent. The attack by the silylating agent traps the intermediate by production of a stable silyl ester having the structure of the class of novel intermediates of this invention.

Since one silyl moiety is required for each sulfenic acid moiety, at least an equimolar ratio of silylating agent to penicillin sulfoxide generally will be necessary. Certain silylating agents are so structured as to generate two or more silyl moieties per molecule. Correspondingly lesser molar quantities of such silylating agents can be employed. Generally, an excess of from about 1.1 to about 4 equivalents of the silylating agent will be employed per equivalent of the penicillin sulfoxide. Correspondingly, and as will be developed in detail hereinafter, certain penicillin sulfoxide starting materials will have additional points at which silylation can occur. In such instances one additional equivalent of the silyl moiety will be required for each such point of silylation.

In preparing the silyl ester intermediate of this invention, any of the above-mentioned silylating agents can be employed. However, strongly, alkaline conditions must be avoided, or cleavage of the β -lactam ring will occur. Therefore, special precautions must be observed in those instances in which a silazane is employed as silylating agent. Since the use of a silazane results in the concomitant production of ammonia during silylation, care must be exercised to assure the immediate neutralization of the ammonia thus produced. This can be accomplished by including in the reaction mixture a minor amount of an acid which inactivates the ammonia upon its generation. A like result can be achieved by employing a combination of the silazane and a halosilane as silylating agent. The halosilane will generate a hydrogen halide as by-product of the silyl ester formation, and the hydrogen halide, in turn, will scavenge the ammonia generated from the silazane.

Conversely, care must be exercised in employing a halosilane as silylating agent. Since a hydrogen halide is formed during such silylation, the acidic conditions thereby developed may cause ring closure immediately to occur. In order to avoid this possibility, it is preferred to employ a mixture of silylating agents containing a sufficient amount of a silazane to neutralize by ammonia formation the hydrogen halide which forms.

The silyl ester intermediate either can be isolated from the silylation reaction mixture, or the silylation reaction mixture can be sub-


jected to acid treatment to achieve ring closure of the silyl ester. Alternatively, the acid can be included with the penicillin sulfoxide in the reaction mixture at the outset of the reaction. Under the latter set of reaction conditions, the silyl ester intermediate will be transient, and ring closure with decomposition of the silyl ester will occur substantially simultaneously with the formation of the silyl ester.

Various acids can be employed in the ring closure portion of the process of this invention. Examples of suitable acids include sulfuric acid, phosphoric acid, and other mineral acids; methanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, and other sulfonic acids; boron trifluoride, ferric chloride, aluminium chloride, and other Lewis acids; and other commonly recognized acidic reagents.


Highly preferred acids are sulfonic acids. Examples of preferred sulfonic acids are the C₁ to C₁₂-hydrocarbonsulfonic acids such as the C₁ to C₁₂-alkanesulfonic acids such as methanesulfonic acid, ethanesulfonic acid, hexane sulfonic acids, nonanesulfonic acids, dodecanesulfonic acids, and the like, as well as the C₁ to C₇-cycloalkanesulfonic acids such as cyclobutanesulfonic acid, cyclopentanesulfonic acid, cyclohexanesulfonic acid, and cycloheptanesulfonic acid, the C₆ to C₁₂ aryl- and alkarylsulfonic acids such as benzenesulfonic acid, dodecylbenzenesulfonic acids, alpha- and beta-naphthalene sulfonic acids, biphenylsulfonic acids, p-toluenesulfonic acid, xylenesulfonic acids, and the like, disulfonic acids such as methanedisulfonic acid, and benzenedisulfonic acid, benzenetrisulfonic acid, mixtures of sulfonic acids, and such sulfonic acids substituted with groups that do not interfere with the ring closure reaction, such as chlorine, bromine, nitro, cyano, and the like, exemplified by p-chlorobenzenesulfonic acid, 3,5-dibromobenzenesulfonic acid, 4-nitro-alpha-naphthalenesulfonic acid, and 4-cyanobenzenesulfonic acid. For economic reasons, the preferred sulfonic acids are C₁ to C₆-alkanesulfonic acids such as methanesulfonic acid, ethanesulfonic acid, and the simple C₆ to C₆ aryl and alkaryl hydrocarbonsulfonic acids such as benzenesulfonic acid, p-toluenesulfonic acid, and the like.

The acidic substance can be employed in a wide range of proportions relative to the silyl ester intermediate. In general, the molar ratio of the silyl ester intermediate to the acidic substance will be from 1:1 to about 100:1. Preferably, a molar ratio of the silyl ester intermediate to the acid ranges from about 5:1 to about 15:1. The concentration of the silyl ester intermediate in the total solvent system can vary extensively, but preferably the silyl ester intermediate constitutes from about 1 to about 20 percent by weight of the reaction mixture.

Preferably, the penicillin sulfoxide which is employed in the process of this invention is one having the formula




- 5 in which R_3 is hydrogen and R_4 is hydrogen; C_1-C_8 alkanoyl; azidoacetyl; cyanoacetyl; haloacetyl;




- 10 in which Ar is phenyl, thienyl, furyl, pyrrolyl, or phenyl substituted with from one to three substituents selected from the group consisting of fluorine, chlorine, bromine, iodine, trifluoromethyl, C_1-C_3 acyloxy, hydroxy, C_1-C_3 alkyl, C_1-C_3 alkoxy, cyano, and nitro;




- 15 in which Ar' is phenyl, pyridyl, or substituted phenyl as defined above, and Y is oxygen or sulfur;



- 20 in which Ar is as defined above, and B is C_1-C_3 acyloxy, hydroxyl, carboxyl, esterified carboxyl, $-CN$, $-N_3$, $-NH_2$ or $-NHR$ in which R is benzyloxycarbonyl, C_1-C_4 alkoxy, cycloalkoxycarbonyl, triphenylmethyl,




or 2,2,2-trichloroethoxycarbonyl; (3-cydnone) C_2-C_3 alkanoyl;



- 30 in which R' is hydrogen or methoxy; 2 - (1H-tetrazol-1-yl) - acetyl; or R_3 and R_4 taken together with the nitrogen atom to which they are bonded are phthalimido, a cyclic imide moiety of a C_8-C_{12} dicarboxylic acid,

- 35 2,2 - dimethyl - 5 - oxo - 4 - phenylimid-


azolidin - 1 - yl, or 2,2 - dimethyl - 3 - nitroso - 5 - oxo - 4 - phenylimidazolidin - 1 - yl; and R_2 is hydrogen, C_1-C_6 alkyl, 2,2,2-trihaloethyl, 2-iodoethyl, benzyl, nitrobenzyl, tetrahydropyranyl, 9-fluorenyl, succinimidomethyl, phthalimidomethyl, methoxybenzyl, dimethoxybenzyl, cyanomethyl, nitrophenyl, dinitrophenyl, 2,4,6-trinitrophenyl, bis(p - methoxyphenyl)methyl, triphenylmethyl, benzhydryl; benzyloxymethyl, C_2-C_6 alkanoyloxymethyl, C_2-C_4 alkanoyl, phenacyl, or a radical of the formula




in which R_1 independently is C_1-C_4 alkyl or phenyl.

The above definitions for R_2 , R_3 and R_4 represent only a portion of the groups now well recognized in the penicillin and cephalosporin arts. Penicillin, sulfoxides containing any of these well known substituents can be readily employed in the ring expansion process of this invention.

As mentioned above, it is contemplated by this invention to employ as starting material the sulfoxide of 6-aminopenicillanic acid (6-APA):



When the above is employed, three points of silylation exist. In accordance with the process of this invention, the stable silyl intermediate which will result during the thermal cleavage will have the formula



in which each R_1 is as defined herein above. Thus, inherent in the process of this invention is the generation from 6-APA of a silyl ester intermediate having both the amino and the carboxy moieties suitably protected. Under the acidic conditions at which ring closure is accomplished to produce the des-acetoxycephalosporin, both additional silyl protecting groups will be cleaved to produce the highly desirable 7-aminodesacetoxycephalosporanic acid (7-ADCA). The process of this invention thus permits the direct con-

version of 6-APA sulfoxide to 7-ADCA. As will be apparent under the conditions of this specific conversion, it is essential that the ratio of silylating agent to 6-APA sulfoxide be such as will afford a minimum of three silyl moieties per each molecule of 6-APA sulfoxide.

It is correspondingly possible to employ as starting material a penicillin sulfoxide which has either a free amino function in the 6-position or a free carboxy function in the 3-position. In such instances the ratio of silylating agent to penicillin sulfoxide will be such as will afford a minimum of two silyl moieties per each molecule of the sulfoxide.

When R_3 of the sulfoxide starting material is hydrogen, R_4 can be hydrogen or a silyl protecting group, such as trimethylsilyl, triethylsilyl, and the like. When R_3 and R_4 are each hydrogen, the resulting silyl ester intermediate which is produced will have one of the hydrogens replaced by the silyl protecting group. When R_4 of the sulfoxide starting material is a silyl protecting group, such silyl protecting group will be retained in the silyl ester intermediate. Upon ring-closure to form the desacetoxycephalosporin product, any silyl group which would have been present at the 7-amino function will be cleaved to produce a cephalosporin in which R_3 and R_4 are both hydrogen.

Representative of the silyl ester intermediates of this invention as well as the penicillin sulfoxides which can be used in and the desacetoxycephalosporins which can be prepared by the process of this invention are those in which R_2 is, for example, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, *sec*-butyl, isobutyl, *t*-butyl, amyl, hexyl, 2,2,2-trichloroethyl, 2,2,2-tribromoethyl, 2-iodoethyl, benzyl, *p*-nitrobenzyl, tetrahydropyranyl, succinimidomethyl, phthalimidomethyl, *p*-methoxybenzyl, cyanomethyl, 3,4-dimethoxybenzyl, *p*-nitrophenyl, 2,4-dinitrophenyl, 2,4,6-trinitrophenyl, bis(*p*-methoxyphenyl)methyl, triphenylmethyl, benzhydryl, benzyloxymethyl, acetoxymethyl, propionoxymethyl, acetyl, propionyl and phenacyl, and the like.

R_2 of the sulfoxide starting material can also be hydrogen or a silyl protecting group, such as trimethylsilyl, triethylsilyl, or triphenylsilyl. When such a starting material is employed, the silyl ester intermediate which is produced will be appropriately silylated in its carboxyl function. In the instance in which R_2 of the sulfoxide is hydrogen the carboxyl function of the silyl ester intermediate will be protected with the silyl group of the silylating agent which has been employed. In the instance in which R_2 of the sulfoxide is itself a silyl protecting group, such group will be retained in the silyl ester intermediate. Upon treatment of this silyl ester intermediate with acid to produce ring-closure, the silyl group which protects the carboxyl function can addi-

tionally be cleaved to produce the corresponding free acid cephalosporin.

In those instances in which R_2 is hydrogen or a silyl protecting group, and the resulting desacetoxycephalosporin product this is a free acid cephalosporin, it has been discovered that it is highly advantageous to isolate the desacetoxycephalosporin product in the form of a salt, specifically its lithium salt. The free acid desacetoxycephalosporin product, although preparable by the process of this invention, is found to be isolatable from the resulting mixture only with some difficulty and, correspondingly, with some loss of product. This problem can be greatly alleviated by converting the free acid product present in the reaction mixture to its corresponding salt, specifically its lithium salt. Conversion of the free acid desacetoxycephalosporin product to its lithium salt can be accomplished by adding to the reaction mixture containing the free acid product an amount of a lithium compound sufficient at least to convert all of the free acid product to the corresponding salt. Typical lithium compounds which can be employed include lithium acetate, lithium hydroxide, lithium lactate, and lithium 2-ethylhexanoate. They can be added to the reaction mixture either alone or in an appropriate solvent. Furthermore, they can be added to the reaction mixture as such or, when in a solvent, to a residue of the reaction mixture containing the free acid cephalosporin product.

The amino group of the penicillin sulfoxides which are used in and the desacetoxycephalosporins which are prepared by the process of this invention can incorporate any of a broad range of substituents. Representative examples of the R_4 substituent when R_3 is hydrogen include the following: formyl, acetyl, propionyl, butyryl, valeryl, caproyl, azidoacetyl, cyanoethyl, chloroacetyl, bromoacetyl, phenylacetyl, 2-thienylacetyl, 3-thienylacetyl, 2-furylacetyl, 3-furylacetyl, 2-pyrrolylacetyl, 3-pyrrolylacetyl, 4-chlorophenylacetyl, 3-trifluoromethylphenylacetyl, 4-hydroxyphenylacetyl, 3-tolylacetyl, 4-cumylacetyl, 4-methoxyphenylacetyl, 3-cyanophenylacetyl, 4-nitrophenylacetyl, phenoxyacetyl, thiophenylacetyl, pyridyloxyacetyl, *p*-nitrophenoxyacetyl, α -aminophenylacetyl, α -benzyloxycarbamidophenylacetyl, α -*t*-butoxycarbamidophenylacetyl, α -formyloxyphenylacetyl, α -cyanophenylacetyl, α -azidophenylacetyl, 3-sydnoneacetyl, 2-(1H-tetrazol-1-yl)acetyl, 2-nitrophenylthio, 2-nitro-4-methoxyphenylthio, and the like. These as well as many other groups are now well recognized in the art.

When R_3 is hydrogen, it is highly preferred that R_4 be phenylacetyl or phenoxyacetyl.

The silyl ester intermediates can likewise contain any of the above substituents as well as many others, with the exception, however,

that a reactive functional group which may be present in the R_2 , R_3 or R_4 substituent of the penicillin sulfoxide may become silylated during formation of the intermediate. Upon ring closure of the thus-formed silyl ester intermediate to produce the desacetoxycephalosporin, the additional silyl group will be cleaved to generate a cephalosporin having the R_2 , R_3 and R_4 substituents as they existed in the penicillin sulfoxide starting material. Illustrative of this is the situation in which R_3 is hydrogen and R_4 is α -aminophenylacetyl. In this instance the α -amino group would be silylated during formation of the silyl ester intermediate. Upon subsequent ring closure this silyl group would be cleaved to regenerate in the thus-formed cephalosporin an α -aminophenylacetyl group at the nitrogen in the 7-position. In view of the above, the definitions of R_2 and R_4 with respect to the penicillin sulfoxide and the silyl ester intermediate will in general correspond except in those instances in which the starting penicillin sulfoxide contains groups which can be silylated. As to such groups, R_2 and R_4 in the definition of the silyl ester intermediates is modified to account for the silylation effect.

When R_3 and R_4 are taken together with the nitrogen atom to which they are bonded, representative examples of the combination include, for example, phthalimido, succinimido, and 2,2 - dimethyl - 5 - oxo - 4 - phenylimidazolidin - 1 - yl.

The prior art describes literally thousands of penicillin compounds which, by the process of this invention, can be converted to desacetoxycephalosporin compounds. Any of the penicillin sulfoxides which are employed as starting materials in the process of this invention are readily available by techniques known in the art. For example, penicillin G (benzylpenicillin) or penicillin V (phenoxymethylpenicillin) can be converted to their corresponding sulfoxides and these used as starting materials in the process of this invention. Both penicillin G and penicillin V are available either naturally or biosynthetically, and both can be readily cleaved to produce 6-APA. 6-APA can itself be oxidized and thereby employed as starting material in this invention. 6-APA also can be modified by acylation in the 6-position and/or esterification in the 3-position according to known techniques, thereby to produce any of the basic penicillin structures, which, in turn, can be oxidized in accordance with prior art techniques to produce the penicillin sulfoxides employed herein as starting materials.

Desacetoxycephalosporin compounds which are produced by the process of this invention from the corresponding penicillin sulfoxides, upon removal of any carboxy and/or other protecting group which might be present, are useful as antibiotics in therapeutic

treatment of diseases caused by various Gram-positive and Gram-negative microorganisms. 7-Aminodesacetoxycephalosporanic acid (7-ADCA), produced from 6-APA sulfoxide by the process of this invention, is additionally useful as an intermediate to prepare other desacetoxycephalosporin antibiotic substances. Furthermore, any of the desacetoxycephalosporin products can be cleaved to produce 7-ADCA. The thus-obtained 7-ADCA can then be acylated, for example, with 2-thiophenacetyl chloride to obtain 7 - (2 - thienyl)acetamido - 3 - methyl - 3 - cephem - 4 - carboxylic acid, a known antibiotic.

Illustrative of the silyl ester intermediates of this invention are the following:

Trimethylsilyl 3 - phthalimido - 4 - oxo - 1 - (1' - methoxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.

Trimethylsilyl 3 - phthalimido - 4 - oxo - 1 - (1' - trimethylsilyloxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate. 85

Trimethylsilyl 3 - phenoxyacetamido - 4 - oxo - 1 - (1' - *p* - nitrobenzyloxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate. 90

Triethylsilyl 3 - phenylacetamido - 4 - oxo - 1 - [1' - (2,2,2 - trichloroethoxycarbonyl) - 2' - methyl - 2' - propenyl] - azetidine - 2 - sulfenate. 95

Trimethylsilyl 3 - trimethylsilylamino - 4 - oxo - 1 - (1' - trimethylsilyloxycarbonyl - 2' - methyl - 2' - propenyl) - azetidine - 2 - sulfenate. 100

Trimethylsilyl 3 - (α - trimethylsilylamino - phenylacetamido) - 4 - oxo - 1 - (1' - *p* - nitrobenzyloxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate. 105

Triphenylsilyl 3 - (2' - thienyl)acetamido - 4 - oxo - 1 - (1' - benzhydryloxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate. 110

Tributylsilyl 3 - (4' - hydroxyphenyl)acetamido - 4 - oxo - 1 - (1' - benzyloxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate. 115

Triphenylsilyl 3 - succinimido - 4 - oxo - 1 - [1' - (2' - iodo)ethyloxycarbonyl - 2' - methyl - 2' - propenyl]azetidine - 2 - sulfenate. 120

Trimethylsilyl 3 - (3' - sydnone)acetamido - 4 - oxo - 1 - (1' - *t* - butoxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate. 125

Trimethylsilyl 3 - (α - trimethylsilyloxy - phenylacetamido) - 4 - oxo - 1 - (1' - *p* - hydroxybenzyloxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.

Trimethylsilyl 3 - (2',2' - dimethyl - 3' - trimethylsilyl - 5' - oxo - 4' - phenylimidazolidin - 1' - yl) - 4 - oxo - 1 - (1' - triphenylsilyloxycarbonyl - 2 - methyl - 2' - propenyl)azetidine - 2 - sulfenate.

- Trimethylsilyl 3 - (2' - furyl)acetamido - 4 - oxo - 1 - [1' - (9 - fluorenyloxycarbonyl) - 2' - methyl - 2' - propenyl]azetidine - 2 - sulfenate.
- 5 Triethylsilyl 3 - (4' - chlorophenyl)acetamido - 4 - oxo - 1 - (1' - *p* - methoxybenzyloxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.
- 10 Trimethylsilyl 3 - formamido - 4 - oxo - 1 (1' - phthalimidomethoxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.
- 15 Tripropylsilyl 3 - (α - benzyloxycarbonyl)phenylacetyl - 4 - oxo - 1 - (1' - *p* - methoxybenzyloxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.
- 20 Trimethylsilyl 3 - (3' - tolyl)acetamido - 4 - oxo - 1 - (1' - tetrahydropyranyloxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.
- 25 Trimethylsilyl 3 - thiophenoxyacetamido - 4 - oxo - 1 - (1' - benzhydryloxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.
- 30 Trimethylsilyl 3 - (2' - pyrrolyl)acetamido - 4 - oxo - 1 - (1' - ethoxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.
- 35 Trimethylsilyl 3 - (3' - thienyl)acetamido - 4 - oxo - 1 - (1' - benzyloxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.
- 40 Trimethylsilyl 3 - [2' - (1H - tetrazol - 1 - yl)acetamido] - 4 - oxo - 1 - (1' - *p* - nitrobenzyloxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.
- 45 Typical conversions of penicillin sulfoxides to desacetoxycephalosporins in accordance with the process of this invention include the following:
- 50 *p* - Nitrobenzyl 6 - phenoxyacetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain *p* - nitrobenzyl 7 - phenoxyacetamido - 3 - methyl - 3 - cephem - 4 - carboxylate.
- 55 *t* - Butyl 6 - (2 - thienyl)acetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain *t* - butyl 7 - (2 - thienyl)acetamido - 3 - methyl - 3 - cephem - 3 - carboxylate.
- 60 2,2,2 - Trichloroethyl 6 - α - aminophenylacetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain 2,2,2 - trichloroethyl 7 - α - aminophenylacetamido - 3 - methyl - 3 - cepham - 4 - carboxylate.
- 65 *p* - Nitrobenzyl 6 - (2',2' - dimethyl - 5' - oxo - 4' - phenylimidazolidin - 1' - yl) - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain *p* - nitrobenzyl 7 - (2',2' - dimethyl - 5' - oxo - 4' - phenylimidazolidin - 1' - yl) - 3 - methyl - 3 - cephem - 4 - carboxylate.
- 70 Benzhydryl 6 - (α - formyloxy)phenylacetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain benzhydryl - 7 - (α - formyloxy)phenylacetamido - 3 - methyl - 3 - cephem - 4 - carboxylate.
- 75 Benzyl 6 - (3 - sydnone)acetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain benzyl 7 - (3 - sydnone)acetamido - 3 - methyl - 3 - cephem - 4 - carboxylate.
- 80 2 - Iodomethyl 6 - [2 - (1H - tetrazol - 1 - yl)]acetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain 2 - iodo-methyl 7 - [2 - (1H - tetrazol - 1 - yl)]acetamido - 3 - methyl - 3 - cephem - 4 - carboxylate.
- 85 6 - Amino - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylic acid to obtain 7 - amino - 3 - methyl - 3 - cephem - 4 - carboxylic acid.
- 90 Triphenylmethyl 6 - succinimido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain triphenylmethyl 7 - succinimido - 3 - methyl - 3 - cephem - 4 - carboxylate.
- 95 Trimethylsilyl 6 - thiophenoxyacetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain 7 - thiophenoxyacetamido - 3 - methyl - 3 - cephem - 4 - carboxylic acid.
- 100 Methyl 6 - (2 - furyl)acetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain methyl 7 - (2 - furyl)acetamido - 3 - methyl - 3 - cephem - 4 - carboxylate.
- 105 *p* - Nitrobenzyl 6 - (N - trimethylsilyl) amino - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain *p* - nitrobenzyl 7 - amino - 3 - methyl - 3 - cephem - 4 - carboxylate.
- 110 Benzhydryl 6 - phenylacetamido - 2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain benzhydryl 7 - phenylacetamido - 3 - methyl - 3 - cephem - 4 - carboxylate.
- 115 Benzyl 6 - (2 - nitrophenyl)sulfenamide - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain benzyl 7 - (2 - nitrophenyl)sulfenamide - 3 - methyl - 3 - cephem - 4 - carboxylate.
- 120 *p* - Nitrobenzyl 6 - (2 - nitro - 4 - methoxyphenyl)sulfenamide - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate to obtain *p* - nitrobenzyl 7 - (2 - nitro - 4 - methoxyphenyl)sulfenamide - 3 - methyl - 3 - cephem - 4 - carboxylate.
- 125 This invention is further illustrated by the following detailed examples.
- EXAMPLE I
- Into a 50 ml., 3-neck flask was placed 752 mg. (2 millimoles) of methyl 6 - phthalimido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate. To the flask were then added 10 ml. of benzene, 0.26 ml. (2 millimoles) of trimethylchlorosilane, and 0.21 ml. (1 millimole) of hexamethyldisilazane. The resulting mixture was stirred and refluxed for about 16 hours at 78–80°C. The reaction mixture was then evaporated *in vacuo* to produce a residue of approximately a quan-

titative yield of trimethylsilyl 3 - phthalimido - 4 - oxo - 1 - (1' - methoxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.

5 Analysis:

Calc. for $C_{20}H_{24}N_2O_5Si$

C, 53.57; H, 5.39; N, 6.25

Found: C, 53.76; H, 5.55; N, 6.42

$[\delta]_D^{27} -164.4^\circ$ (Benzene)

10 UV_{MAX} 220 m μ ($\epsilon=47,200$) 291 m μ ($\epsilon=10,500$)

IR 2990, 2930, 1770, 1760, 1735, 1715, 1390, 1245, 874, 845 and 705 cm⁻¹.

15 NMR (δ) 0.05 (s, 9H), 20.4 (s, 3H), 3.84 (s, 3H), 5.07 (two overlapping s), 5.20 (6s, 1H), 5.84 (s, AB, 2H), 7.86 (m, 4H).

20 MS m/e 448, 433, 359, 327, 299, 293, 262, 239, 204, 187, 172, 160, 113, 104, 89, 73.

EXAMPLE II

To a suspension of 376 mg. of methyl 6 - phthalimido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate in 10 ml. of benzene was added 0.25 ml. of N₂O - bis(trimethylsilyl)acetamide. The resulting mixture was heated to reflux (about 78°C.) for about 22 hours. The reaction mixture was cooled to room temperature and evaporated *in vacuo* to produce a brown gum which exhibited an NMR spectrum consistent for the expected trimethylsilyl ester intermediate, trimethylsilyl 3 - phthalimido - 4 - oxo - 1 - (1' - methoxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.

EXAMPLE III

To a 50 ml. 3-neck flask was added 752 mg. (2 millimoles) of methyl 6 - phthalimido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate in 10 ml. of benzene. To the resulting mixture was added 0.26 ml. (2 millimoles) of trimethylchlorosilane and 0.21 ml. (1 millimole) of hexamethyldisilazane. The resulting mixture was refluxed overnight at a temperature of between 80 and 83°C after which the mixture was cooled to room temperature and evaporated *in vacuo* to produce a clear very viscous liquid. IR analysis established the presence of a β -lactam ring. MS analysis indicated the following m/e values: 448, 433, 389, 327, 359, 299, 293, 262, 239, 204, 187, 172, 160, 152, 130, 120, 113, 104, 89 and 73. NMR analysis was consistent for the expected trimethylsilyl ester intermediate, trimethylsilyl 3 - phthalimido - 4 - oxo - 1 - (1' - methoxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.

A sample of the above trimethylsilyl ester intermediate was treated with one equivalent of methanesulfonic acid in a 1:1 volume mixture of benzene and dimethylacetamide. The mixture was permitted to stand at room temperature overnight. The reaction mixture was then evaporated to dryness *in vacuo* at about 55°C. The residue was dissolved in a small amount of benzene and placed on a 1.5 $\times$ 21 cm. silica gel column. The sample was eluted from the column using 100 ml. quantities of benzene, 5% ethyl acetate in benzene, 10% ethyl acetate in benzene, and 15% ethyl acetate in benzene. Fractions of 20 ml. each were collected. Methyl 7 - phthalimido - 3 - methyl - 3 - cephem - 4 - carboxylate in a yield of about 50% was obtained from fractions 7, 8, 9, and 10.

Analysis:

NMR (CDCl₃) (δ) 2.34 (s, 3H), 3.39 (d, J=16 and 47, 2H), 3.85 (s, 3H), 5.12 (d, J=4.5, 1H), 5.42 (d, J=4.5, 1H), and 7.82 (m, 4H).

IR (CHCl₃) 3020, 2970, 1800, 1785, 1725, 1390, 1220, 1110, and 907 cm⁻¹.

EXAMPLE IV

A mixture of 752 mg. (2 millimoles) of methyl 6 - phthalimido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate, 393 mg. (3 millimoles) of N-trimethylsilylacetamide, and 10 ml. of benzene was refluxed (78°C.) for about 16 hours. The reaction mixture was then cooled to room temperature and evaporated *in vacuo* to a glassy solid residue. NMR of the residue was consistent for the trimethylsilyl ester intermediate, trimethylsilyl 3 - phthalimido - 4 - oxo - 1 - (1' - methoxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.

The residue was redissolved in 10 ml. of benzene, and 20 mg. (0.2 millimole) of methanesulfonic acid dissolved in 2 ml. of a 60:40 mixture of dimethylacetamide and benzene was added. The resulting mixture was stirred at room temperature for about 16 hours. Thin-layer chromatography (TLC) of the reaction mixture showed the presence of a major amount (estimated greater than 70%) of methyl 7 - phthalimido - 3 - methyl - 3 - cephem - 4 - carboxylate.

EXAMPLE V

Into a 50 ml. 3-neck flask were placed 994 mg. (2 millimoles) of p-nitrobenzyl 6 - phthalimido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate, 10 ml. of benzene, 0.26 ml. (2 millimoles) of trimethylchlorosilane, and 0.21 ml. (1 millimole) of hexamethyldisilazane. The mixture was heated to reflux (78°-80°C.) with stirring for about 16 hours. A small amount of solid formed in the reaction mixture and was filtered off. The

filtrate was evaporated to dryness *in vacuo* to recover a yellow gum which by IR and NMR analysis was shown to be trimethylsilyl 3 - phthalimido - 4 - oxo - 1 - (1' - *p* - nitrobenzyloxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.

NMR (CDCl₃) (δ) 0.05 (s, 9H), 2.09 (s, 3H), 5.14 (s, 1H), 5.33 (two overlapping s, 2H), 5.37 (s, 2H), 5.97 (s, 2H), 7.86 (s, 4H), 7.91 (q, 4H, J = 90 and 40).

IR (CHCl₃) 3050, 2960, 1840, 1785, 1725, 1640, 1500, 1100, and 846 cm⁻¹.

EXAMPLE VI

To 50 ml. of benzene were added 1.75 grams (5 millimoles) 6 - phthalimido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylic acid, 1.3 ml. (10 millimoles) of trimethylchlorosilane, and 1.05 ml. (5 millimoles) of hexamethyldisilazane. The mixture was refluxed (78°—80°C.) for about 4.5 hours. The reaction mixture was then cooled to room temperature and evaporated *in vacuo* to produce a residue of trimethylsilyl 3 - phthalimido - 4 - oxo - 1 - (1' - trimethylsilyloxy-carbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate in approximately quantitative yield.

Analysis:

Calc. for C₂₂H₃₀N₂O₆Si₂
C, 52.15; H, 5.97; N, 5.53; S, 6.32

Found
C, 51.98; H, 5.85; N, 5.58; S, 6.18

[δ]_D²⁷ -45.4° (Benzene)

IR (CHCl₃) 3010, 2960, 1795, 1775, 1740, 1725, 1382, 1250, 1063, 844, and 707 cm⁻¹.

NMR (CDCl₃) (δ) 0.05 (s, 9H), 0.37 (s, 9H) 2.05 (s, 3H), 5.01 (s, 1H), 5.12 (s, 1H), 5.20 (s, 1H), 5.84 (s, AB pattern, 2H), and 7.84 (m, 4H).

MS m/e 506, 491, 416, 401, 388, 300, 299, 232, 230, 204, 187, 160, 147, 132, 114, 104, 73.

EXAMPLE VII

To a 250 ml., 3-neck flask were added 50 ml. of benzene, 2.6 grams (about 20 millimoles) of N-trimethylsilylacetamide, and 1.75 grams (5 millimoles) of 6 - phthalimido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylic acid. The mixture was stirred for about 5 minutes, after which solution was about complete. The mixture was then heated slowly to reflux (about 80°C.) and maintained thereat for about 5 hours. The mixture was then cooled to room temperature, during

which time a minor amount of solid crystallized out. The solid was filtered, and the filtrate was evaporated to dryness *in vacuo* to produce a residue confirmed by NMR analysis to be trimethylsilyl 3 - phthalimido - 4 - oxo - 1 (1' - trimethylsilyloxy-carbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.

EXAMPLE VIII

To a solution of 380 mg. (1 millimole) of methyl 6 - phenoxyacetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate in 15 ml. of dry toluene maintained at 40°C. were added 330 mg. (about 2 millimoles) of N-trimethylsilylacetamide and 0.023 ml. (about 0.2 millimole) of trimethylchlorosilane. The resulting mixture was refluxed at about 111°C. for about 5 hours. The reaction mixture was then cooled to room temperature and evaporated *in vacuo* to a brown gummy solid residue. NMR analysis established that the residue contained trimethylsilyl 3 - phenoxyacetamido - 4 - oxo - 1 - (1' - methoxycarbonyl - 2' - methyl - 2' - propenyl)azetidine - 2 - sulfenate.

NMR (CDCl₃) 0.05 (s, 9H), 2.04 (s, 3H), 3.75 (s, 3H), 4.54 (s, 2H), 5.07 (s, 2H), 5.47 (s, 1H), 5.67 (q, J = 4.5 and 8.0, 1H), 6.17 (d, J = 4.5, 1H), 7.85 (d, J = 8.0, 1H).

EXAMPLE IX

To a solvent mixture of 25 ml. of 60% toluene and 40% acetonitrile were added 1.25 grams (2.5 millimoles) of *p* - nitrobenzyl 6 - phenoxyacetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate, 1.0 gram (7.5 millimoles) of N-trimethylsilylacetamide, and 0.19 ml. (1.5 millimoles) of trimethylchlorosilane. The mixture was heated reflux (about 87°C.) and maintained thereat for about 20 hours. The mixture was then cooled to room temperature, and about 0.17 ml. of methane-sulfonic acid was added. The mixture was then stirred at room temperature for about 16 hours. A minor amount of solid formed in the mixture. The solid was removed by filtration, and the filtrate was shown by thin-layer chromatography (TLC) to contain principally *p*-nitrobenzyl 7 - phenoxyacetamido - 3 - methyl - 3 - cephem - 4 - carboxylate.

EXAMPLE X

To a mixture of 25 ml. of benzene and 18 ml. of dimethylacetamide were added 2.5 grams (5 millimoles) of *p* - nitrobenzyl 6 - phenoxyacetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate, 2 grams (about 15 millimoles) of N-trimethylsilylacetamide, and 0.19 ml. (1.5 millimoles) of trimethylchlorosilane. The resulting mixture was heated to reflux (91°C.). The mixture was refluxed for about 20 hours, after which time it was

cooled to room temperature and 0.11 ml. of methanesulfonic acid was added. The mixture was then stirred at room temperature for about 16 hours. The reaction mixture was then evaporated in vacuo to a residue. The residue was dissolved in about 20 ml. of benzene. A minor amount of insoluble crystalline material remained which was filtered off. The filtrate was then passed onto a silica gel chromatographic column, and the sample eluted therefrom using successively 200 ml. of 5% ethyl acetate in benzene, 100 ml. of 10% ethyl acetate in benzene, and 400 ml. of 15% ethyl acetate in benzene to recover *p*-nitrobenzyl 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylate.

EXAMPLE XI

Into a 250 ml. 3-neck flask were placed 25 ml. of dimethylacetamide, 62.5 ml. of dry toluene, 1.84 grams (14 millimoles) of *N*-trimethylsilylaceta-
 20 midamide, and 0.091 ml. (1.4 millimoles) of methanesulfonic acid. To the resulting mixture was added 5.0 grams (10 millimoles) of *p*-nitrobenzyl 6-phenoxyacetamido-2,2-dimethylpenam-1-oxide-3-carboxylate. The mixture was refluxed (115°C.) for about 1.5 hours, after which the resulting dark red solution was evaporated in vacuo to a residue of about 10 grams. The residue was cooled and seeded with a small amount of *p*-nitrobenzyl 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylate, after which crystallization began. Ethanol (50 ml.) was slowly added to complete crystallization of the product. The solid was filtered, washed with ethanol, and vacuum dried to yield 2.6 grams of *p*-nitrobenzyl 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylate.

EXAMPLE XII

To a mixture of 25 ml. of dimethylacetamide and 62 ml. of dry toluene were added 1.31 grams (10 millimoles) of *N*-trimethylsilylaceta-
 45 midamide and 5.0 grams (10 millimoles) of *p*-nitrobenzyl 6-phenoxyacetamido-2,2-dimethylpenam-1-oxide-3-carboxylate. The mixture was refluxed at 118°C. for about 0.5 hour, after which the resulting light brown solution was cooled to about 80°C. and 0.065 ml. (1 millimole) of methanesulfonic acid was added. The mixture was then reflux at 118°C. for an additional hour. The brown solution was evaporated in vacuo to a residue of about 10 grams. The residue was cooled and seeded, after which crystallization began to occur. About 50 ml. of ethanol was slowly added, and the resulting mixture was filtered. The solid was washed with additional ethanol and vacuum-dried overnight at 40°C. to yield 2.0 grams of *p*-nitrobenzyl 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylate.

EXAMPLE XIII

To a mixture of 50 ml. of benzene and 37.5 ml. of dimethylacetamide was added 5.0 grams (10 millimoles) of *p*-nitrobenzyl 6-phenoxyacetamido-2,2-dimethylpenam-1-oxide-3-carboxylate. To the resulting solution were then added 1.26 ml. (10 millimoles) of trimethylchlorosilane and 1.05 ml. (5 millimoles) of hexamethyldisilazane. The mixture was refluxed at 95°C. for 14.5 hours, and the resulting dark red mixture was then cooled to room temperature. To the mixture was then added 0.058 ml. (0.9 millimole) of methanesulfonic acid. The mixture was stirred for 15 minutes at about 30°C. and then stirred for about 100 minutes at 55°C. The reaction mixture was then evaporated to near dryness and 10 ml. of ethanol was added. Crystals began to form after about hour, at which time an additional 30 ml. of ethanol was added. The mixture was refrigerated for three days, and the crystals were filtered. The crystals were redissolved in 5 ml. of dioxane to which was then added 15 ml. of ethanol. Crystals began slowly to form. The crystals were filtered, washed with ethanol and dried to yield 550 mg. of *p*-nitrobenzyl 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylate.

EXAMPLE XIV

A mixture of 5.0 grams (10 millimoles) of *p*-nitrobenzyl 6-phenoxyacetamido-2,2-dimethylpenam-1-oxide-3-carboxylate in 60 ml. of dioxane was prepared and warmed to about 40°C. To this warmed mixture were added 1.26 ml. (10 millimoles) of trimethylchlorosilane and 1.05 ml. (5 millimoles) of hexamethyldisilazane. The resulting mixture was heated slowly to a temperature of 100°C. and maintained thereat for about 5 hours during which time it turned from a light yellow solution to a light brown solution.

The mixture was then cooled to about 40°C. and 0.04 ml. of boron trifluoride etherate was added. The solution turned slightly red and stirring at room temperature was continued for about 16 hours. The reaction mixture was then evaporated to near dryness in a rotary evaporator. The residue was recrystallized from 20 ml. of a 1:3 mixture of dioxane and ethanol containing about 1 ml. of dimethylacetamide to produce *p*-nitrobenzyl 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylate.

EXAMPLE XV

To a mixture of 25 ml. of benzene and 19 ml. of dimethylacetamide were added 2.45 grams (5 millimoles) of 2,2,2-trichloroethyl 6-phenoxyacetamido-2,2-dimethylpenam-1-oxide-3-carboxylate, 1.7 grams (about 10 millimoles) of *N*-trimethylsilylaceta-
 120 midamide and 0.035 ml. (0.5 millimole) of methane-

sulfonic acid. The mixture was refluxed at 95–96°C. for 15.5 hours. The reaction mixture was then extracted three times with water, and the benzene layer was dried over magnesium sulfate. NMR and TLC analyses established the structure of the product present in the benzene layer to be 2,2,2 - trichloroethyl 7 - phenoxyacetamido - 3 - methyl - 3 - cephem - 4 - carboxylate.

- 10 NMR (CDCl₃) (δ) 2.20 (s, 3H), 3.20 and 3.57 (2d, 2H), 4.55 (s, 2H), 4.87 (d, 2H), 5.03 (d, J=4.5, 1H), 5.83 (d, J=4.5 and 8.0, 1H), 6.80–7.40 (m, 5H), 7.94 (d, J=8.0, 1H).

EXAMPLE XVI

- 15 A solution of 1.41 grams (3 millimoles) of p - nitrobenzyl 6 - phenylacetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylate in 30 ml. of dioxane was prepared. To the resulting solution were added 17 ml. of dry benzene followed by 730 mg. (4.5 millimoles) of N-trimethylsilylacetylacetamide and 0.06 ml. of trimethylchlorosilane. The resulting mixture was refluxed at 84°C. for 16 hours. The reaction mixture, a light yellow, clear solution, was cooled to about 50°C., and 0.002 ml. of methanesulfonic acid was added. The mixture was then maintained at about 50°C., stirred for two hours, and then evaporated to dryness *in vacuo*. The residue, unable to be recrystallized from ethanol, remained in the form of a gum which, by TLC analysis, was shown to contain p - nitrobenzyl 7 - phenylacetamido - 3 - methyl - 3 - cephem - 4 - carboxylate.

EXAMPLE XVII

- 40 To 20 ml. of dioxane was added 700 mg. (3 millimoles) of 6-aminopenicillanic acid sulf-oxide, and the resulting mixture was warmed to about 60°C. A tiny drop of trifluoroacetic acid was added followed by 1.3 grams (about 10 millimoles) of N-trimethylsilylacetylacetamide, the trifluoroacetic acid being added to neutralize a trace of triethylamine impurity present in the N-trimethylsilylacetylacetamide. The mixture was heated to reflux for about 3 hours, during which time the mixture turned to a red-brown color but remained clear. The mixture was then evaporated to dryness *in vacuo* to produce a red-brown gum.

- 50 The gum was dissolved in 20 ml. of dry benzene, and 0.02 ml. of methanesulfonic acid was added and the mixture stirred at 50°C. for 2.5 hours. The mixture was cooled to room temperature and 10 ml. of methanol was added dropwise followed by 5.0 ml. of water. A solid precipitated from the mixture, and the mixture was stirred for about 20 minutes, filtered, and the filtrate was evaporated under vacuum. The residue was then suspended in water, and aqueous sodium bicarbonate solution was added to pH 8.0.

The solid dissolved at this pH, and the pH was then adjusted to 3.5 by addition of acid, and a precipitate formed. The precipitate was filtered, and dried *in vacuo* to give 40 mg. of a material established by TLC, IR, and UV to be 7 - amino - 3 - methyl - 3 - cephem - 4 - carboxylic acid.

IR (mull) 2960, 2870, 1800, 1620, 1530, 1350, 795, and 786 cm⁻¹.

IV max (pH 6.8 buffer)
262 mμ (ε=72,000)
245 mμ (ε=62,500).

EXAMPLE XVIII

To about 100 ml. of toluene were added 3.82 grams of 6 - phenoxyacetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylic acid, about 4 grams of N-trimethylsilylacetylacetamide, and 0.07 ml. of methanesulfonic acid. The mixture was refluxed at 111°C. for about 16 hours. To the tarry dark brown reaction mixture 30 ml. of methanol was added. A TLC of the reaction mixture indicated the presence of 7 - phenoxyacetamido - 3 - methyl - 3 - cephem - 4 - carboxylic acid. The reaction mixture was evaporated to dryness *in vacuo*, and 25 ml. of acetonitrile was added to the residue. Insolubles were filtered off, and the filtrate was evaporated *in vacuo*. About 25 ml. of ethyl acetate was added to the residue. The ethyl acetate solution was extracted with 25 ml. of saturated aqueous sodium bicarbonate. The aqueous layer was then separated, washed with 25 ml. of ethyl acetate, separated, and slurried with an additional 25 ml. of ethyl acetate. The pH of the resulting mixture was adjusted to about 3.3 by addition of concentrated HCl. The aqueous layer was separated from the ethyl acetate layer, and the ethyl acetate layer was washed with 25 ml. of water. The ethyl acetate was then extracted with 25 ml. of saturated aqueous sodium bicarbonate. The aqueous sodium bicarbonate was washed twice with 25 ml. of ethyl acetate and then slurried with an additional 25 ml. of ethyl acetate and the pH adjusted to about 2.5 by addition of concentrated HCl. The ethyl acetate layer was separated and washed with 25 ml. of water. Activated charcoal and MgSO₄ was added to the ethyl acetate layer; the mixture was stirred for about 30 minutes and filtered. The filtrate was evaporated to about 20 ml., seeded, and refrigerated to produce crystalline 7 - phenoxyacetamido - 3 - methyl - 3 - cephem - 4 - carboxylic acid.

EXAMPLE XIX

To 45 ml. of dry toluene were added 3.1 g. (about 19 millimoles) of N-trimethylsilylacetylacetamide and 3.31 g. (7.65 millimoles) of N-nitrosohetacillin sulfoxide [6 - (2,2 - dimethyl - 3 - nitroso - 5 - oxo - 4 - phenyl-

imidazolidin - 1 - yl) - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylic acid]. The mixture was stirred for about 15 minutes, and 5 ml. of N,N-dimethylacetamide containing 15 drops of methanesulfonic acid were added. The mixture was refluxed at 110°—111°C. for about 2 hours and then cooled to about 40° C. Methanol (10 ml.) was added, and the solvents were evaporated *in vacuo*. The residue was dissolved in 35 ml. of ethyl acetate, slurried with an equal volume of water, and the pH was adjusted to 7 by addition of 30% sodium hydroxide solution. The aqueous layer was separated from the organic layer, and the aqueous layer was slurried with 35 ml. of ethyl acetate. The pH of the mixture was adjusted to 2 by addition of 40% phosphoric acid. The ethyl acetate layer was separated, dried, and evaporated to produce a gummy residue which was dissolved in 30 ml. of saturated sodium bicarbonate solution. A solution of 1.32 g. (3.6 millimoles) of N,N-dibenzylethylenediamine diacetate in 25 ml. of water was added, and the solution was stirred for several hours in 50 ml. of methyl isobutyl ketone. The mixture was filtered, and the filtered product was washed with a mixture of acetone and water to give 0.56 g. of the N,N-dibenzylethylenediamine diacetate salt of 7 - (2,2 - dimethyl - 3 - nitroso - 5 - oxo - 4 - phenylimidazolidin - 1 - yl) - 3 - methyl - 3 - cephem - 4 - carboxylic acid, from which 112 mg. of the free acid was crystallized in ethyl acetate by addition of phosphoric acid. NMR spectrum of the product was consistent with the free acid structure.

EXAMPLE XX

To 90 ml. of dry benzene were added 3.5 g. (10 millimoles) of 6 - phthalimido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylic acid and 5 g. of distilled N-trimethylsilylacetamide. The mixture was stirred at room temperature for about 15 minutes and then heated to reflux (80°—82°C.) and stirred for about 5 hours. The mixture was then cooled to about 45°C., and 0.65 ml. (10 millimoles) of methanesulfonic acid in 10 ml. of N,N-dimethylacetamide were added dropwise. The mixture was stirred at 45°C. for about 30 minutes, and thin-layer chromatograph (TLC) of a sample of the reaction mixture indicated the presence of 7 - phthalimido - 3 - methyl - 3 - cephem - 4 - carboxylic acid.

EXAMPLE XXI

To a stirred mixture of 1.75 g. (5 millimoles) of 6 - naphthalimido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylic acid in 45 ml. of benzene were added 1.3 ml. (10 millimoles) of trimethylchlorosilane and 1.05 ml. (5 millimoles) of hexamethyldisilazane. The mixture was refluxed to 80°C. for about 5 hours. A mixture of 0.03 ml. (0.5 milli-

mole) of methanesulfonic acid in 5 ml. of N,N-dimethylacetamide was added, and the mixture was stirred at room temperature for about 1 hour. Analysis of a sample of the reaction mixture by TLC indicated the presence of 7 - phthalimido - 3 - methyl - 3 - cephem - 4 - carboxylic acid.

EXAMPLE XXII

From a mixture of 80 ml. of toluene and 16 ml. of N,N-dimethylacetamide, 20 ml. were taken, and 2 g. (about 12.5 millimoles) of N-trimethylsilylacetamide were added thereto. To the remainder of the solvent mixture 7.0 g. (20 millimoles) of 6 - phenylacetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylic acid and 8 g. (about 50 millimoles) of N-trimethylsilylacetamide were added. The mixture was stirred at room temperature for about 30 minutes, and then 52 ml. (8 millimoles) of methanesulfonic acid were added. The mixture was heated to reflux (114°C.). During heating, and when the temperature of the mixture reached about 90° C., the previously prepared solution of N-trimethylsilylacetamide was added gradually over a 1 hour period. The mixture was refluxed for a total of 2.5 hours. The reaction mixture then was cooled to room temperature, and 40 ml. of methanol were added. The mixture was evaporated *in vacuo* at about 60°C. The resulting oily residue was then added to a solution of 4.2 g. (40 millimoles) of lithium acetate in 40 ml. of methanol. The mixture was stirred for about 1 hour, and the crystallized lithium salt of 7 - phenylacetamido - 3 - methyl - 3 - cephem - 4 - carboxylic acid was filtered, washed with acetone, and dried *in vacuo* to obtain 1.2 g. (18%). The NMR spectrum and TLC were consistent for the expected cephalosporin product.

EXAMPLE XXIII


A mixture of 450 ml. of dry toluene and 50 ml. of N,N-dimethylacetamide was prepared, and 100 ml. of the mixture were used to dissolve 5 g. (about 31 millimoles) of N-trimethylsilylacetamide. To the remainder of the solvent mixture were added 19.1 g. (54 millimoles) of 6 - phenoxyacetamido - 2,2 - dimethylpenam - 1 - oxide - 3 - carboxylic acid and 20 g. (about 125 millimoles) of N-trimethylsilylacetamide. The mixture was stirred at room temperature for about 30 minutes, and 1.3 ml. (20 millimoles) of methanesulfonic acid were then added. The reaction mixture was then heated to reflux (about 114°C.). During heating, and when the temperature of the mixture reached about 90°C., dropwise addition of the previously prepared N-trimethylsilylacetamide solution was begun and continued over about a 90 minute period. The reaction mixture was allowed to reflux for a total of about 105

minutes. Heating was then discontinued, and the reaction mixture was cooled to room temperature in an ice bath. Methanol (100 ml.) was added, and the reaction mixture was stirred for about 15 minutes. The mixture was evaporated *in vacuo* at 60°C. A solution of 30 g. (about 300 millimoles) of lithium acetate in 100 ml. of methanol was then added to the oily residue of the reaction mixture. The resulting mixture was stirred for about 1 hour at room temperature, and the resulting crystalline product was filtered, air dried, and then vacuum dried overnight at room temperature to give 13.6 g. (about 74%) of crude product. The product was purified by slurrying in 25 ml. of acetone, filtering, and washing with ether, to give 12.1 g. (65.5%) of the lithium salt of 7 - phenoxyacetamido - 3 - methyl - 3 - cephem - 4 - carboxylic acid.


WHAT WE CLAIM IS:—

1. A process for converting a penicillin sulfoxide to a desacetoxycephalosporin which comprises heating the penicillin sulfoxide in an inert, substantially anhydrous solvent to a temperature of from about 75°C to about 150°C. in the presence of a silylating agent containing at least one readily cleavable moiety having the formula $-\text{Si}(\text{R}_1)_3$ in which each R_1 independently is C_1-C_4 alkyl or phenyl, and either isolating a stable intermediate silyl ester of an azetidine - 2 - sulfonate and subsequently converting said ester to the corresponding desacetoxycephalosporin by treatment thereof with an acidic compound in an inert substantially anhydrous solvent, or without isolation, converting the intermediate silyl ester to the corresponding desacetoxycephalosporin by treating the reaction mixture with an acidic compound.

2. Process of claim 1, wherein the penicillin sulfoxide has the formula I




in which R_3 is hydrogen and R_4 is hydrogen; C_1-C_8 alkanoyl; azidoacetyl; cyanoacetyl; haloacetyl;



in which Ar is phenyl, thienyl, furyl, pyrrolyl, or phenyl substituted with from one to three substituents selected from the group consisting of fluorine, chlorine, bromine, iodine, trifluoromethyl, C_1-C_3 acyloxy, hydroxy, C_1-C_3 alkyl, C_1-C_3 alkoxy, cyano and nitro;




in which Ar' is phenyl, pyridyl or substituted phenyl as defined above and Y is oxygen or sulfur;




in which Ar is as defined above, and B is C_1-C_3 acyloxy; hydroxyl, carboxyl, esterified carboxyl; $-\text{CN}$, $-\text{N}_3$, $-\text{NH}_2$, or $-\text{NHR}$ in which R is benzyloxycarbonyl, C_1-C_4 alkoxycarbonyl, cycloalkoxycarbonyl, triphenylmethyl,



or 2,2,2-trichloroethoxycarbonyl; (3-sydnone)- C_2-C_3 alkanoyl;



in which R' is hydrogen or methoxy; 2 - (1H-tetrazol - 1 - yl)acetyl; or R_3 and R_4 taken together with the nitrogen atom to which they are bonded are phthalimido, a cyclic imide moiety of a C_3-C_{12} dicarboxylic acid or 2,2 - dimethyl - 5 - oxo - 4 - phenylimidazolidin - 1 - yl, or 2,2 - dimethyl - 3 - nitroso - 5 - oxo - 4 - phenylimidazolidin - 1 - yl, and R_2 is hydrogen, C_1-C_6 alkyl, 2,2,2-trihaloethyl, 2-iodoethyl, benzyl, nitrobenzyl, tetrahydropyranyl, 9-fluorenyl, succinimidomethyl, phthalimidomethyl, methoxybenzyl, dimethoxybenzyl, cyanomethyl, nitrophenyl, dinitrophenyl, 2,4,6-trinitrophenyl, bis(p-methoxyphenyl)methyl, triphenylmethyl, benzhydryl, benzyloxymethyl, C_2-C_6 alkanoyloxymethyl, C_2-C_4 alkanoyl, phenacyl, or a radical of the formula



in which each R_1 independently is C_1-C_4 alkyl or phenyl.

3. The process of claim 2 wherein R_2 is as defined in claim 2 and R_3 and R_4 taken together with the nitrogen atom to which they are bonded are 2,2 - dimethyl - 3 - nitroso - 5 - oxo - 4 - phenylimidazolidin - 1 - yl.




minutes. Heating was then discontinued, and the reaction mixture was cooled to room temperature in an ice bath. Methanol (100 ml.) was added, and the reaction mixture was stirred for about 15 minutes. The mixture was evaporated *in vacuo* at 60°C. A solution of 30 g. (about 300 millimoles) of lithium acetate in 100 ml. of methanol was then added to the oily residue of the reaction mixture. The resulting mixture was stirred for about 1 hour at room temperature, and the resulting crystalline product was filtered, air dried, and then vacuum dried overnight at room temperature to give 13.6 g. (about 74%) of crude product. The product was purified by slurrying in 25 ml. of acetone, filtering, and washing with ether, to give 12.1 g. (65.5%) of the lithium salt of 7 - phenoxyacetamido - 3 - methyl - 3 - cephem - 4 - carboxylic acid.


WHAT WE CLAIM IS:—

1. A process for converting a penicillin sulfoxide to a desacetoxycephalosporin which comprises heating the penicillin sulfoxide in an inert, substantially anhydrous solvent to a temperature of from about 75°C to about 150°C. in the presence of a silylating agent containing at least one readily cleavable moiety having the formula $-\text{Si}(\text{R}_1)_3$ in which each R_1 independently is C_1-C_4 alkyl or phenyl, and either isolating a stable intermediate silyl ester of an azetidine - 2 - sulfenate and subsequently converting said ester to the corresponding desacetoxycephalosporin by treatment thereof with an acidic compound in an inert substantially anhydrous solvent, or without isolation, converting the intermediate silyl ester to the corresponding desacetoxycephalosporin by treating the reaction mixture with an acidic compound.

2. Process of claim 1, wherein the penicillin sulfoxide has the formula I




in which R_3 is hydrogen and R_4 is hydrogen; C_1-C_8 alkanoyl; azidoacetyl; cyanoacetyl; haloacetyl;



in which Ar is phenyl, thienyl, furyl, pyrrolyl, or phenyl substituted with from one to three substituents selected from the group consisting of fluorine, chlorine, bromine, iodine, trifluoromethyl, C_1-C_3 acyloxy, hydroxy, C_1-C_3 alkyl, C_1-C_3 alkoxy, cyano and nitro;




in which Ar' is phenyl, pyridyl or substituted phenyl as defined above and Y is oxygen or sulfur;




in which Ar is as defined above, and B is C_1-C_3 acyloxy; hydroxyl, carboxyl, esterified carboxyl; $-\text{CN}$, $-\text{N}_3$, $-\text{NH}_2$, or $-\text{NHR}$ in which R is benzyloxycarbonyl, C_1-C_4 alkoxy, cycloalkoxy, triphenylmethyl,



or 2,2,2-trichloroethoxycarbonyl; (3-sydnone)- C_2-C_3 alkanoyl;



in which R' is hydrogen or methoxy; 2 - (1H-tetrazol - 1 - yl)acetyl; or R_3 and R_4 taken together with the nitrogen atom to which they are bonded are phthalimido, a cyclic imide moiety of a C_3-C_{12} dicarboxylic acid or 2,2 - dimethyl - 5 - oxo - 4 - phenylimidazolidin - 1 - yl, or 2,2 - dimethyl - 3 - nitroso - 5 - oxo - 4 - phenylimidazolidin - 1 - yl, and R_2 is hydrogen, C_1-C_6 alkyl, 2,2,2-trihaloethyl, 2-iodoethyl, benzyl, nitrobenzyl, tetrahydropyranyl, 9-fluorenyl, succinimidomethyl, phthalimidomethyl, methoxybenzyl, dimethoxybenzyl, cyanomethyl, nitrophenyl, dinitrophenyl, 2,4,6-trinitrophenyl, bis(p-methoxyphenyl)methyl, triphenylmethyl, benzhydryl, benzyloxymethyl, C_2-C_6 alkanoyloxymethyl, C_2-C_4 alkanoyl, phenacyl, or a radical of the formula




in which each R_1 independently is C_1-C_4 alkyl or phenyl.


3. The process of claim 2 wherein R_2 is as defined in claim 2 and R_3 and R_4 taken together with the nitrogen atom to which they are bonded are 2,2 - dimethyl - 3 - nitroso - 5 - oxo - 4 - phenylimidazolidin - 1 - yl.

4. Process of claim 2, wherein the silylating agent which is employed has the formula

(a)




in which each R_1 independently is C_1 — C_4 alkyl or phenyl, R''' is hydrogen, C_1 — C_4 alkyl, or phenyl, and X is



in which J is hydrogen or $-\text{Si}(\text{R}_1)_3$ in which each R_1 independently is C_1 — C_4 alkyl or phenyl, or X is $-\text{CW}_3$ in which each W independently is hydrogen, trifluoromethyl, or C_1 — C_3 alkyl;

(b)




in which R_1 and W are as herein defined;

(c)



in which R_1 is as herein defined and Z is halogen, C_2 — C_3 alkenyloxy, C_1 — C_3 alkyl- SO_3 , $-\text{O}-\text{Si}(\text{R}_1)_3$, $-\text{S}-\text{Si}(\text{R}_1)_3$ in which R_1 is as herein defined, or



in which R_5 is hydrogen or C_1 — C_3 alkyl, and R_6 is C_1 — C_4 alkyl or $-\text{Si}(\text{R}_1)_3$ in which R_1 is as herein defined, or R_5 and R_6 taken together with the nitrogen atom to which they are bonded form a heterocyclic ring having 5 or 6 atoms, up to 3 of which, in addition to the already-defined nitrogen atom, independently are nitrogen, sulfur, or oxygen.

5. The process of claim 3 wherein the silylating agent which is employed is as defined in claim 4.

6. Process of claim 4, wherein the silylating agent is selected from N_2O - bis(trimethylsilyl)acetamide, N_2O - bis(trimethylsilyl)trifluoroacetamide, N - trimethylsilylacetamide, N - methyl - N - trimethylsilylacetamide, N - trimethylsilyl - N,N' - diphenylurea, propenoxytrimethylsilane, trimethylsilyl methane sulfonate, trimethylchlorosilane, hexamethyldisilazane, N - trimethylsilyl - t - butylamine, N - trimethylsilyldiethylamine, N - trimethylsilylimidazole, hexamethyldisiloxane, hexamethyldisilthiane and mixtures of any of the above.

7. The process of claim 3 wherein the silylating agent is as defined in claim 6.

8. Process of claim 6, wherein the acidic compound is a sulfonic acid.

9. Process of claim 7 wherein the acidic compound is a sulfonic acid.

10. Process of claim 8, wherein the acidic compound is C_1 — C_{12} hydrocarbonsulfonic acid.

11. Process of claim 9, wherein the acidic compound is a C_1 — C_{12} hydrocarbonsulfonic acid.


12. Process of claim 10, wherein the acidic compound is methanesulfonic acid.

13. Process of claim 11, wherein the acidic compound is methanesulfonic acid.

14. Process of claim 12, in which the silylating agent comprises N-trimethylsilylacetamide, N_2O - bis(trimethylsilyl)acetamide, or a mixture of hexamethyldisilazane and trimethylchlorosilane.

15. Process of claim 13, in which the silylating agent comprises N-trimethylsilylacetamide, N_2O - bis(trimethylsilyl)acetamide or a mixture of hexamethyldisilazane and trimethylchlorosilane.

16. Process of claim 8 or 9, wherein R_2 is hydrogen or a radical of the formula



and R_1 is C_1 — C_4 alkyl or phenyl and the reaction mixture containing the resulting free acid desacetoxycephalosporin is treated with a lithium compound to produce the corresponding lithium salt of the desacetoxycephalosporin.

17. Process of claim 16, in which the lithium compound is lithium acetate.

18. Process of claim 8, in which R_3 is hydrogen and R_4 is phenylacetyl or phenoxyacetyl.


19. Silyl esters of azetidine - 2 - sulfenates of the formula II




17

1,412,856


17




- in which each R_1 independently is C_1-C_4 alkyl or phenyl; R_2 is C_1-C_6 alkyl, 2,2,2-trihaloethyl, 2-iodoethyl, benzyl, nitrobenzyl, tetrahydropyranyl, 9-fluorenyl, succinimido-methyl, phthalimidomethyl, methoxybenzyl, dimethoxybenzyl, cyanomethyl, nitrophenyl, dinitrophenyl, 2,4,6-trinitrophenyl, bis(*p*-methoxyphenyl)methyl, triphenylmethyl, benzhydryl, benzyloxymethyl, C_2-C_6 alkanoxymethyl, C_2-C_6 alkanoyl, phenacyl, or a radical of the formula




- 15 in which each R_1 is as herein defined, R_2 is hydrogen and R_4 is C_1-C_6 alkanoyl; azidoacetyl, cyanoacetyl, haloacetyl;




- 20 in which Ar is phenyl, thienyl, furyl, pyrrolyl, or phenyl substituted with from one to three substituents selected from the group consisting of fluorine, chlorine, bromine, iodine, trifluoromethyl, C_1-C_3 acyloxy, $-OSi(R_1)_3$ in which each R_1 is as herein defined, C_1-C_3 alkyl, C_1-C_3 alkoxy, cyano, and nitro;




in which Ar' is phenyl, pyridyl, or substituted phenyl as defined above and Y is oxygen or sulfur;




- 30 in which Ar is as defined above and B is C_1-C_3 acyloxy,



in which each R_1 is as herein defined, esterified carboxyl, $-CN$, $-N_3$, or $-NHR$ in which R is benzyloxycarbonyl, C_1-C_4 alkoxy carbonyl, cycloalkoxy carbonyl, triphenyl methyl,



2,2,2-trichloroethoxycarbonyl, or $-Si(R_1)_3$ in which R_1 is as herein defined; (3-syndnone)- C_2-C_3 alkanoyl;



in which R' is hydrogen or methoxy; 2-(1H-tetradol-1-yl)acetyl; or R_3 and R_4 taken together with the nitrogen atom to which they are bonded are phthalimido, a cyclic imide moiety of a C_3-C_{12} dicarboxylic acid, 2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl, or 2,2-dimethyl-3-nitroso-5-oxo-4-phenylimidazolidin-1-yl.

20. The compound of claim 19 wherein R_1 and R_2 independently are as defined in claim 19 and R_3 and R_4 taken together with the nitrogen atom to which they are bonded are phthalimido, a cyclic imide moiety of a C_3-C_{12} dicarboxylic acid or 2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl.

21. The compound of claim 19 wherein R_3 and R_4 are taken together with the nitrogen atom to which they are bonded are 2,2-dimethyl-3-nitroso-5-oxo-4-phenylimidazolidin-1-yl.

22. Compound of claim 20, in which R_1 is methyl.


23. Compound of claim 21, in which R_1 is methyl.

24. Compound of claim 22, in which R_2 is



in which each R_1 independently is C_1-C_4 alkyl or phenyl.

25. Compound of claim 23, in which R_2 is



in which each R_1 independently is C_1-C_4 alkyl or phenyl.


26. Compound of claim 19, in which R_3



is hydrogen and R_1 is phenylacetyl or phenoxycetyl.

27. Compound of claim 26, in which R_1 is methyl.

5 28. Compound of claim 27, in which R_2 is



in which each R_1 independently is C_1-C_4 alkyl or phenyl.

10 29. A process according to claim 1, substantially as herein described with particular reference to any one of Examples IV or IX to XVIII.

30. A process for producing the intermedi-

ate compound of claim 19 substantially as herein described with particular reference to any one of Examples I to VIII. 15

31. A process according to claim 1, substantially as herein described with particular reference to any one of Examples XIX to XXIII. 20

32. Desacetoxycephalosporin when prepared by the process of any one of claims 1, 2, 4, 6, 8, 10, 12, 14 or 29.

33. Desacetoxycephalosporin when prepared by the process of any one of claims 3, 5, 7, 9, 11, 13, 15 to 18 or 31. 25

LANGNER PARRY,
Chartered Patent Agents,
Chichester House,
278-282 High Holborn,
London, W.C.1.
Agents for the Applicants.

Printed for Her Majesty's Stationery Office, by the Courier Press, Leamington Spa, 1975.
Published by The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.